Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Compass Therapeutics
Exelixis
Mayo Clinic
Mayo Clinic
Ohio State University
ViroMissile, Inc.
Children's Oncology Group
Essen Biotech
Seattle Children's Hospital
OHSU Knight Cancer Institute
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
MacroGenics
City of Hope Medical Center
xCures
SAPU NANO (US) LLC
Guerbet
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Hoffmann-La Roche
Dysplasia Diagnostics Limited
Elephas
Mayo Clinic
Incyte Corporation
University of Pittsburgh
Mayo Clinic
NeoTX Therapeutics Ltd.
AccSalus Biosciences, Inc.
Twinpig Biolab, Inc.
West China Hospital
DualityBio Inc.
National Institutes of Health Clinical Center (CC)
Coherus Oncology, Inc.
University of Pittsburgh
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
HiFiBiO Therapeutics
Massachusetts General Hospital
7 Hills Pharma, LLC
Travera Inc
Pfizer
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Cancer Research UK